Hepatitis C is a kind of viral hepatitis mainly transmitted by blood transfusion (plasma) and injection, etc. It was confirmed in 1989, and the pathogen causing the disease is called Hepatitis C virus, which is the main cause of post-transfusion hepatitis. Hepatitis C can be characterized by general weakness and a lack of appetite, but most patients may have no obvious symptoms, often without jaundice, only repeated elevation of transaminases, so it is not easy to be detected at an early stage. The disease is easy to be chronic, research confirms that about 60%～85% of acute hepatitis C can be turned into chronic, and continue to progress, and closely related to the occurrence of liver cirrhosis and primary hepatocellular carcinoma, which is very harmful to human health. Since hepatitis C was prevalent among blood donors in China from the mid-1980s to the early 1990s, blood and plasma transfusions have caused a considerable amount of hepatitis C. In the past few years, the number of hepatitis C infections in China has been increasing, and the number of hepatitis C infections has been increasing. Since 1993, when freeze-dried plasma was banned in China and blood donors were screened for hepatitis C antibodies, post-transfusion hepatitis C has been significantly reduced, but it still occurs from time to time. It has been reported that professional blood donors, even when screened for hepatitis C antibodies, can still infect about 10% of recipients with hepatitis C virus. Since October 1998, the introduction of mandatory blood donation and the elimination of professional blood donation have further reduced the incidence of hepatitis C virus infection. Whether hepatitis C can be diagnosed early and treated correctly directly affects the prognosis of patients. At present, experts at home and abroad have reached a consensus on the treatment of hepatitis C, that is, the only recognized and effective treatment is the antiviral therapy using ordinary interferon or polyethylene glycolized interferon combined with oral ribavirin (viral azole); this treatment plan can make the vast majority of patients to achieve therapeutic effects, and some patients can be cured. Unfortunately, since most patients with hepatitis C do not have obvious symptoms, it is often difficult to detect and diagnose in time, thus losing the time for treatment, or even progressing to cirrhosis, and losing the opportunity to apply interferon for antiviral treatment. Therefore, to improve the prognosis of hepatitis C, it should be detected and treated as early as possible. To achieve early detection and timely treatment of hepatitis C should pay attention to: 1. The high-risk groups of hepatitis C include: those who have a history of blood donation, especially those who have a history of plasma donation; those who have received blood transfusion or plasma history, those who have maintained hemodialysis and those who have received organ transplantation before 1993; those who have used blood products before 1995; those who have injected drugs into veins; those who have been infected with HIV; the babies born to mothers who are infected with HCV; and those who have been exposed to HCV by needlestick, knife injury or mucous membrane exposure, Healthcare workers, first-aiders or security personnel who have been exposed to HCV-positive blood by needle stick, knife wound or mucous membrane; people who have had unsafe sex; patients who have undergone surgery, hemodialysis, interventional diagnosis and treatment, etc.; all of them should go to specialized hospitals regularly to check their liver function, hepatitis C antibody and hepatitis C virus RNA, so as to detect it at an early stage. 2, when clearly suffering from hepatitis C, due to the different conditions of each patient, different physical conditions, and interferon has some side effects. Therefore, before interferon antiviral treatment, it should be clear whether there is hepatitis C virus in the patient’s body and whether there are contraindications, and under the guidance of doctors who have experience in treatment, antiviral treatment and follow-up observation should be carried out.